ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 34.4% in July

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 27,635 shares, a decline of 34.4% from the June 30th total of 42,119 shares. Approximately 2.4% of the shares of the company are short sold. Based on an average daily volume of 36,764 shares, the short-interest ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

NDRA has been the subject of several research reports. Ascendiant Capital Markets reduced their target price on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.00.

Institutional Investors Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises about 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent quarter. 1.19% of the stock is currently owned by hedge funds and other institutional investors.

ENDRA Life Sciences Price Performance

Shares of NDRA traded up $0.25 during mid-day trading on Friday, reaching $4.58. The company had a trading volume of 3,419 shares, compared to its average volume of 63,662. ENDRA Life Sciences has a twelve month low of $2.96 and a twelve month high of $9.85. The company’s 50-day moving average is $5.01 and its 200-day moving average is $4.61. The company has a market capitalization of $5.82 million, a P/E ratio of -0.56 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.14. As a group, equities analysts expect that ENDRA Life Sciences will post -4.11 EPS for the current fiscal year.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.